INTRODUCTION
Disease classification is the process of categorizing illnesses in a larger framework of medical conditions. The principle of classifying diseases is important for highlighting links between diseases and creating schemes for diagnostic approaches, thus guiding treatment decisions ( Fig. 1 ). Classification differs from nomenclature, which essentially deals with names and definitions of diseases without focusing on their arrangement. While classification establishes the general concepts, classification criteria provide working schemes that, based on one or more than one characteristics combined, allow the dichotomous classification of a given disease against all others with high confidence.
Classification schemes can be based on histology, cause, biology or clinical characteristics, or may use a mixture of these characteristics to subcategorize diseases. To create mutually exclusive subsets, the most distinctive features should be ranked highest in the hierarchy of classification, but such choices are not necessarily straightforward, and variations in the types and order of classification features used eventually result in dissimilar classification schemes. Practitioners may want a classification system that is functional for daily care and allows a sound approach to diagnosis and management.
Multiple classification systems for vasculitis have been generated over the past 60 years [1] [2] [3] [4] [5] [6] . The numerous iterations of classification schemes reflect the complexity involved in establishing a simple vasculitis classification scheme. Because of the heterogeneous and protean nature of vasculitis, identifying natural subgroups is difficult and we have limited knowledge about their causes. Also, improved diagnostic techniques have led to reappraising the boundaries of diseases, thus prompting the need for revisiting outdated classifications and adding further complexity to represent the diverse diagnostic approaches in a simple classification scheme.
The field of vasculitis classification has recently been invigorated by the publication of the revised 2012 Chapel Hill Consensus Conference (CHCC) for the nomenclature of vasculitis [7 && ]. This international collaborative effort evolved from the 1994 CHCC nomenclature [8] and provides a comprehensive and updated view on the naming and definitions of vasculitis entities. The nomenclature also provided a fairly detailed subcategorization scheme and therefore included elements for the classification of vasculitis. Similarly, the field of classification criteria for vasculitis is evolving and has resulted in the publication of new classification criteria for cryoglobulinemic vasculitis [9] and Behçet's disease [10 && ]. Here, we review the current state of knowledge in the fields of classification and classification criteria for vasculitis. Particular emphasis is placed on the analysis of the strengths and limitations of current vasculitis classification concepts and their usefulness in clinical practice. Table 1 summarizes the entities classified as vasculitis and the main subcategories according to the 2012 CHCC nomenclature. This system recognizes a dozen vasculitis entities that newly incorporate a few diseases, such as Behçet's disease, Cogan's syndrome and hypocomplementic urticarial vasculitis [7 && ]. The highest-order classification level used in the 2012 CHCC nomenclature distinguishes primary systemic, secondary and single-organ vasculitis. This separation has practical implications, because the latter two categories require distinct management approaches. This separation leads to the situation, although seemingly illogical, that a given vasculitis entity (e.g. polyarteritis nodosa, cryoglobulinemic vasculitis) can appear in both classes of primary and secondary vasculitis. Even though single-organ vasculitis is considered a separate group, this vasculitis form can also be primary or secondary in nature; thus, single-organ and secondary vasculitis are not mutually exclusive.
GENERAL CONCEPT OF VASCULITIS CLASSIFICATION

Primary systemic vasculitis
Primary systemic vasculitis has long been subcategorized by the size of vessels mainly involved in the inflammatory process and this pays tribute to the predilection of specific vasculitis entities for particular compartments of the vasculature. The 2012 CHCC nomenclature continued to adopt this main compartmentalization scheme. In addition to the three classical categories of large, medium and small-vessel vasculitis, the 2012 CHCC nomenclature created a class for various vessel-size vasculitis
KEY POINTS
The classification of vasculitis is challenging because of the heterogeneous and protean nature of these illnesses.
The 2012 revision of the Chapel Hill Consensus Conference nomenclature for vasculitis retained the primary reliance on the size of the affected vessels, but added several important categories, subcategories and individual diseases.
An important limitation in the current concept of vasculitis classification, which is mainly pathologybased, is its relatively little practicability to guide diagnostic decisions at the bedside.
Generally accepted sets of operational classification criteria are yet available for most of the main vasculitis entities, but for some entities, there is an unmet need for effective criteria. to accommodate Behçet's disease and Cogan's syndrome. Further subclassification occurred for the class of small-vessel vasculitis divided into immune complex and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [7 && ]. Although appealing in its simplicity, classifying primary systemic vasculitis by the caliber of involved vessels has practical shortcomings. Despite the acceptability of inferring the size of the affected vessel also by imaging studies or by surrogate markers for small-vessel involvement (e.g. glomerulonephritis, palpable purpura or ANCA), the size of the vessel involved is not always demonstrable in individual patients with vasculitis. For some of the entities [e.g. Kawasaki disease, granulomatosis with polyangiitis (GPA; Wegener's), eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss), Behçet's disease], a subset of patients may lack patent expression of vascular involvement. In addition, the range of vessel sizes affected by the vasculitis entities grouped in one category commonly overlaps with those from the other categories. In a vasculitis-positive biopsy, the assignment of an inflamed vessel to the medium or smallsized vessel category is not easy because of changes in the vessel anatomy with the inflammatory process. Consequently, the difficulties in determining the category of vasculitis based on size of the affected vessel may result in misclassification. Similarly, the use of findings of circulating immune complexes or immune deposits in any tissue sample for reliably discriminating vasculitis entities can be questioned. ANCA certainly is a dominant classification trait, but is not applicable to the subset of diseases classified as ANCAassociated vasculitis with no detectable ANCAs.
Nomenclature
Classification and classification criteria Diagnosis
Secondary vasculitides (with known or probable cause)
Secondary vasculitis encompasses the subgroup of diseases thought to be caused by an underlying condition or exposure. The main vasculitis causes are systemic diseases (e.g., rheumatoid arthritis), cancer, drug exposure, and infection, but the number of factors with a definitely established pathogenic link to vasculitis remains small. The most prominent known causes of vasculitis are infection with hepatitis B virus (linked with polyarteritis nodosa) and hepatitis C virus (linked with cryoglobulinemic vasculitis), and use of antithyroid compounds and levamisole-contaminated cocaine (both linked to ANCA-associated vasculitis). Many other infectious agents and medicinal products have been occasionally found as potential triggers or causes of various vasculitis entities, but the strength of evidence is low. Nonetheless, discriminating a secondary vasculitis category is highly relevant because such cases can benefit from a cause-based management.
Single-organ vasculitis
Single-organ vasculitis, previously also called 'localized', 'limited', 'isolated' or 'nonsystemic' vasculitis, denotes vasculitis restricted to a single organ or organ system, such as cutaneous, peripheral nerve or gastrointestinal single-organ vasculitis. Further subcategorization of singleorgan vasculitis into unifocal or diffuse forms has been suggested [7 && ,11] to differentiate the entities involving organs or organ systems covering large areas of the human body from those with limited anatomic extent that could be cured surgically. Single-organ vasculitis must be differentiated from limited forms of systemic vasculitides, such as localized GPA (Wegener's) or renal-limited ANCA-associated vasculitis, which may progress to systemic disease forms. Because a disease presenting as single-organ vasculitis may only be the initial phase of a systemic disease, single-organ vasculitis can only be classified retrospectively after a minimal time has elapsed with no progression to systemic vasculitis. A 6-month period with no progression to systemic disease has been suggested as a cut-off [12] .
Areas of uncertainty and future directions
Although vasculitis classification has become increasingly elaborated, some areas remain illdefined. Individual vasculitis cases with nonspecific presentations may still be difficult to assign to a specific disease entity. For example, leucocytoclastic cutaneous vasculitis with joint involvement could be considered immunoglobulin A (IgA) vasculitis (with no immune deposits), microscopic polyangiitis (with negative ANCA test results) or polyarteritis nodosa (with no medium-sized vessel disease seen in tissue). Such cases could also be classified as undifferentiated vasculitis, but this concept is not widely accepted. A general aspect needing clarification relates to the potentially misleading effect of the vessel-size-based nature of vasculitis classification, which implies that vessel inflammation must be manifest in any case of vasculitis. This situation recently led to considering that classification of EGPA should be reserved for the subset of cases with histologically or clinically obvious features of vasculitis and should no longer include cases with features considered to primarily reflect eosinophilic proliferation [13] . Changes may also occur for the classification of the combined group of GPA and microscopic polyangiitis. Recent data from observational studies [14] , genetic studies [15] and cluster analysis [16 & ] support a subclassification of this disease group by ANCA specificity (i.e. proteinase 3 or myeloperoxidase-ANCA) than clinical phenotype.
A crucial question is how the current classification schemes can be transposed into clinical practice to correctly classify real patients' vasculitis. This problem is, to some extent, hypothetical, because in many cases, vasculitis presentation immediately suggests a specific vasculitis entity. However, in other instances, classification guidance may be desirable, but, as previously suggested, the histology-based nature of the current classification systems and the high rank placed on vessel caliber in the categorization is suboptimal for clinical practice. Figure 2 outlines an alternative, clinical-based classification algorithm for vasculitis. Analogous to a classification algorithm proposed for cutaneous vasculitis [17] , our proposed algorithm ranks testing for ANCA and cryoglobulin as top discriminators for classes of primary systemic vasculitis entities. Because of its potential practical usefulness and because no attempt has been made to obtain agreement on the ranking of selected features, further efforts may be needed to achieve consensus on such a clinical-based classification tree.
CLASSIFICATION CRITERIA FOR SELECTED VASCULITIS ENTITIES
Classification criteria are working tools that serve as inclusion criteria for clinical trials or other research to standardize patient populations and to provide with confidence that the analyzed patients truly have the disease under investigation. Classification criteria should differentiate a given vasculitis from its vasculitis peers, but also from other nonvasculitic conditions that mimic vasculitis. Even more so than classification, classification criteria must encapsulate the essential elements by which a given disease is defined.
Various methodologies are used to develop classification criteria that range from use of expert opinion to network analyses. Classification criteria also differ as to whether their operating characteristics (e.g. sensitivity and specificity) have been formally assessed. For example, the Lanham criteria for EGPA [18] and the American Heart Association criteria for Kawasaki disease [19] have never undergone formal evaluation, but are nevertheless widely accepted because they are clinically sound. Some sets, such as the modified American College of Rheumatology (ACR) criteria for GPA [20] , consist of slight ad-hoc adjustments to previously published criteria.
Confusion derives from the claim of some published criteria that they are 'diagnostic' rather than classification criteria [21] [22] [23] . This semantic distinction has no methodological underpinning in terms of the developmental aspects of such 'diagnostic criteria' as compared with those presented as classification criteria. Unlike classification criteria, true diagnostic criteria should be both 100% sensitive and 100% specific [24] , which seems out of reach for diseases whose diagnoses do not rely on a single pathognomonic test. In the context of vasculitis, the term 'classification criteria' thus seems more appropriate than 'diagnostic criteria'. GCA FIGURE 2. Outline of a practical approach to vasculitis classification. Some entities, such as Kawasaki disease, antiglomerular basement membrane, hypocomplementemic urticarial vasculitis and Cogan's syndrome, are not included for simplification and because of the specific appearance of these vasculitis entities, so their differential classification from other vasculitis entities is not relevant. ANCAs, antineutrophil cytoplasmic antibodies; EGPA, eosinophilic granulomatosis with polyangiitis (Churg-Strauss); GCA, giant-cell arteritis; GPA, granulomatosis with polyangiitis (Wegener's); IgA, immunoglobulin A; MPA, microscopic polyangiitis, PAN, polyarteritis nodosa.
Well accepted classification criteria are available for most of the vasculitis entities ( for several vasculitis entities for adult or children populations, respectively. Another collaborative international effort has led to the publication of the European Medicines Agency (EMA) algorithm [29] , and many additional individual efforts have led to the publication of criteria for single entities.
ACR criteria
The ACR criteria represent the first and still most comprehensive set of classification criteria for several forms of vasculitis, but they must be understood within the context of their developmental features [35] . The ACR criteria were derived from a dataset with patient data for several vasculitis entities, and the seven generated sets of criteria therefore essentially differentiate one vasculitis from the remaining vasculitis forms. Consequently, the ACR criteria do not allow distinguishing the given vasculitis from other nonvasculitic conditions and should be used for only illnesses for which a vasculitis diagnosis has been previously ascertained. Despite these limitations, the ACR criteria have proven very useful for giant-cell arteritis [25] , Takayasu arteritis [26] , GPA [30] and EGPA [18] , but much less for IgA vasculitis [26] , polyarteritis nodosa [28] and hypersensitivity vasculitis [36] .
Pediatric EULAR/PRINTO/PRES classification criteria
The EULAR/PRINTO/PRES criteria revisited the classification criteria for four vasculitis entities that primarily or occasionally occur in childhood, namely IgA vasculitis, GPA, polyarteritis nodosa and Takayasu arteritis [27] , because specific criteria were needed for pediatric cases with these diseases. Like the ACR criteria, the individual sets of criteria were derived from a large database by comparison with the remaining cases of other vasculitis diagnoses as controls, which implies that they should be used for only cases with a priori knowledge of vasculitis. Of note, the criteria for GPA, polyarteritis nodosa and Takayasu arteritis also seem to have face validity for adult cases.
European Medicines Agency algorithm
The purpose of the EMA algorithm [29] , sometimes referred to as 'Watts' criteria', was to harmonize the classification of polyarteritis nodosa and ANCAassociated vasculitis. The primary scope was for patient populations analyzed in epidemiologic studies, but the tool is applicable to other research areas. The EMA algorithm does not represent an original classification system per se because it was mainly built by using various elements of the CHCC nomenclature [8] and ACR criteria [35] . The major advantage of this system is that it provides a hierarchy of classifying the four vasculitides under consideration. As well, the algorithm provides a detailed definition for the entry criteria -clinical, laboratory, histological or imaging characteristicsto ensure that the algorithm is used for cases only with some evidence of vasculitis, and it includes a subgroup of undifferentiated vasculitis. The main strength of the algorithm appears to be its good ability to unequivocally classify the diseases within the subcategory of ANCA-associated vasculitis [37] .
Other classification criteria
Numerous other classification criteria, focusing on single vasculitis entities, are available and are regularly used ( Table 2 ). The recently added classification criteria for cryoglobulinemic vasculitis [9] and the international criteria for Behçet's disease [10 && ] stem from international collaborations and were evaluated on the basis of real patient data. The international criteria for Behçet's disease were found more sensitive than the previous International Study Group criteria [21] , although at the expense of specificity.
The classification of giant-cell arteritis based on the sole criterion of positive temporal artery biopsy findings likely represents the most simple classification system and highlights the close link of diagnosis and classification. In clinical practice, a positive temporal artery biopsy is considered a stringent diagnostic criterion, although false-negative cases exist, and it can sporadically be observed in other vasculitis entities. Because a positive temporal artery biopsy is not 100% specific to giant-cell arteritis, it is not a definite and stand-alone criterion to diagnose giant cell arteritis in a given patient but it still can be considered as an acceptable classification criterion to be applied to patient populations. This being said, a limitation of temporal artery biopsy for classifying giant-cell arteritis is the lack of a consensus on the microscopic findings required to comply with a histological diagnosis of giant-cell arteritis.
Limitations and future directions
A number of unresolved or new matters remain to be addressed. Polyarteritis nodosa, microscopic polyangiitis and adult IgA vasculitis (Henoch-Schönlein) are likely the most challenging diseases in terms of generally accepted classification criteria. The ACR criteria for IgA vasculitis are poorly specific, and although enhanced criteria are now available for pediatric cases [27] , similarly improved criteria need to be devised for adults. Microscopic polyangiitis has no proper classification system, but can be classified by using the EMA algorithm [29] .
Polyarteritis nodosa is problematic as well, and we lack confidence in the value of the ACR criteria [28] . For EGPA, the major difficulty is distinguishing it from hypereosinophlic syndrome [38] .
Adjustments will have to be made for other vasculitis entities to account for shifting diagnostic paradigms. For example, with giant-cell arteritis, imaging techniques are increasingly being used to document vessel inflammation instead of temporal artery biopsy. The changing practices currently result in an inadequacy of the ACR criteria for discriminating giant-cell arteritis and the need for updated criteria incorporating imaging findings. In general, classification criteria developed by using only vasculitis cases as controls should be applied for only cases also satisfying a minimal set of vasculitis entry characteristics to ensure that they are used in the correct setting.
CONCLUSION
Undoubtedly, progress has been made in the classification of vasculitis, which reflects the increasing knowledge about the natural history of this group of diseases and refined diagnostic skills. The list of illnesses categorized as vasculitis has become more extensive, and the incorporation of secondary vasculitis and single-organ vasculitis in the classification spectrum of the 2012 CHCC nomenclature has been important. Several international efforts have been undertaken to produce widely acceptable classification criteria for virtually all vasculitis entities and now offer a solid basis to homogenize patient populations enrolled in research studies.
The classification of vasculitis, however, remains a challenge, and further evolution is expected. The most important challenge is the current disconnect of the classification systems from clinical practice, which may indicate that the current general classification scheme of vasculitis, although conceptually accurate, is of limited use in clinical practice. With respect to the unmet needs in the area of classification criteria, further progress in the near future is being anticipated to come from the 'diagnostic and classification criteria for vasculitis (DCVAS)' study [39 & ] currently underway.
